Results 101 to 110 of about 86,092 (288)

Natriuretic Peptide Receptor A as a Novel Target for Prostate Cancer

Molecular Cancer, 2011
Background The receptor for the cardiac hormone atrial natriuretic peptide (ANP), natriuretic peptide receptor A (NPRA), is expressed in cancer cells, and natriuretic peptides have been implicated in cancers. However, the direct role of NPRA signaling in
Kong Xiaoyuan, Hellermann Gary, Patel Ronil, Mohapatra Shyam S, Raulji Payal, Wang Xiaoqin, Vera Pedro L, Meyer-Siegler Katherine L, Coppola Domenico, Mohapatra Subhra   +9 more
doaj   +1 more source

Retrospective study of the association between neutering status and changes secondary to degenerative mitral valve disease [PDF]

, 2019
Dissertação de Mestrado Integrado em Medicina VeterináriaMyxomatous mitral valve disease is the most common cardiovascular disease reported in dogs. Although many patients may remain asymptomatic, some of them progress to left-sided congestive heart ...
Silva, Ana Margarida Ribeiro da
core  

Epidemiology of hospitalized heart failure in France based on national data over 10 years, 2012–2022

ESC Heart Failure, Volume 12, Issue 2, Page 1283-1294, April 2025.
Abstract Aims We aim to describe the incidence of HF hospitalization in France in the post‐pandemic era, the prevalence of HF cases and patients' characteristics, management and outcomes while focusing on sex, age and socio‐economic differences and to analyse time‐trends between 2012 and 2022.
Valérie Olié, Richard Isnard, Françoise Pousset, Clémence Grave, Jacques Blacher, Amélie Gabet   +5 more
wiley   +1 more source

Possibilities of Using Blood Natriuretic Peptide Levels as Biomarkers of Morbidity and Aging

Juvenis Scientia
This brief review examines the prospects for the practical use of natriuretic peptide levels as biomarkers of aging and morbidity. A comparison of discrete and continuous methods for assessing these indicators is made.
Dzeranova, N.Y., Isakov, V.A., Pozdnyakova, T.D., Kholkina, A.A.   +3 more
doaj   +1 more source

Natriuretic peptides and integrated risk assessment for cardiovascular disease. an individual-participant-data meta-analysis [PDF]

, 2016
BACKGROUND: Guidelines for primary prevention of cardiovascular diseases focus on prediction of coronary heart disease and stroke. We assessed whether or not measurement of N-terminal-pro-B-type natriuretic peptide (NT-proBNP) concentration could enable ...
Adam S, Butterworth, Andreas, Luchner, Angela M, Wood, Brendan, M. Everett, Børge G, Nordestgaard, Caroline, N. Kistorp, Christie M, Ballantyne, Christopher, Defilippi, Daniel F, Freitag, Daniel, Levy, Demosthenes, B. Panagiotakos, DI ANGELANTONIO, EMANUELE, Frank, Kee, Goya Wannamethee, S, James A, de Lemos, Jari A. Laukkanen, Maryam Kavousi, Jens, Rosenberg, Johan, Ärnlöv, John, Danesh, Jonas, Andersson, Jorge R, Kizer, Juan Pablo, Casas, Jukka, T. Salonen, Jussi, Kauhanen, Lars, Lind, Lisa, Pennells, Lori B, Daniels, Mary, Cushman, Michael, Hecht Olsen, Michael, Sweeting, Nancy, R. Cook, Naveed, Sattar, Olle, Melander, Oscar, H. Franco, Paul M, Ridker, Pei, Gao, Peter, Willeit, Rajiv, Chowdhury, RUBATTU, Speranza Donatella, Rudolf, A. de Boer, Sarah, A. Spackman, Simon G, Thompson, Stefan, Kiechl, Stella, Trompet, Stephen Kaptoge, Paul Welsh, Stephen, Burgess, Suzanne, Judd, Thomas, Mueller, Torben, Jørgensen, Toshiharu, Ninomiya, Veikko, Salomaa, Vijay, Nambi, Vilmundur, Gudnason, Wayne, D. Rosamond   +53 more
core   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Prognostic role of TAPSE to PASP ratio in outpatients with left ventricular systolic dysfunction

ESC Heart Failure, Volume 12, Issue 2, Page 912-922, April 2025.
Abstract Aims Few data are available regarding the role of tricuspid annulus plane systolic excursion to pulmonary artery systolic pressure (TAPSE/PASP), a measurement of right ventricular to pulmonary artery coupling, in patients with chronic heart failure and left ventricular systolic dysfunction.
Mauro Riccardi, Matteo Pagnesi, Rossana Corso, Antonio M. Sammartino, Daniela Tomasoni, Riccardo M. Inciardi, Carlo M. Lombardi, Marianna Adamo, Savina Nodari, Marco Metra   +9 more
wiley   +1 more source

Association of BMI with adherence and outcome in heart failure patients treated with wearable cardioverter defibrillator

ESC Heart Failure, Volume 12, Issue 2, Page 1295-1303, April 2025.
Abstract Background Obesity is a known risk factor for cardiovascular disease (CVD), yet an ‘obesity paradox’ has been observed in various CVD contexts. The impact of obesity on heart failure (HF) patients treated with a wearable cardioverter‐defibrillator (WCD) remains underexplored.
Mohammad Abumayyaleh, Katharina Koepsel, Julia W. Erath, Thomas Kuntz, Norbert Klein, Boldizsar Kovacs, Firat Duru, Ardan M. Saguner, Christian Blockhaus, Dong‐In Shin, Fabienne Kreimer, Michael Gotzmann, Hendrik Lapp, Thomas Beiert, Assem Aweimer, Andreas Mügge, Christel Weiß, Ibrahim El‐Battrawy, Ibrahim Akin   +18 more
wiley   +1 more source

Reframing the role of glucagon‐like peptide 1 receptor agonists in cardiovascular medicine

ESC Heart Failure, Volume 12, Issue 2, Page 923-926, April 2025.
Riccardo M. Inciardi, Alvin Chandra, Ambarish Pandey, Marco Metra   +3 more
wiley   +1 more source

Sacubitril/valsartan preserves regional cardiac function following myocardial infarction in rats

ESC Heart Failure, Volume 12, Issue 2, Page 1304-1315, April 2025.
Parts of the figure were drawn by using pictures from Servier Medical Art. Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License (https://creativecommons.org/licenses/by/3.0/). Abstract Aims Sacubitril/valsartan (Sac/Val) is used for treatment of heart failure. The effect of Sac/Val on regional dysfunction
Einar Sjaastad Nordén, Bård Andre Bendiksen, Kaja Knudsen Bergo, Emil Knut Stenersen Espe, Gary McGinley, Almira Hasic, Ida Marie Hauge‐Iversen, Hege Katrin Ugland, Xin Shen, Michael Frisk, Nishani S. Mabotuwana, William E. Louch, Rizwan I. Hussain, Lili Zhang, Ivar Sjaastad, Alessandro Cataliotti, Geir Christensen   +16 more
wiley   +1 more source